FDA Approves Jemperli Immunotherapy to Treat Rectal Cancer Without Surgery or Chemotherapy

On October 19, 2026, the U.S. Food and Drug Administration granted accelerated approval to a monoclonal antibody that clears a specific genetic form of rectal cancer without requiring a scalpel or radiation beam. The decision authorizes Jemperli, known generically as dostarlimab-gxly, for adult patients whose tumors carry a specific genetic signature.[1][4]

The approval targets locally advanced rectal cancer that is mismatch repair-deficient, or dMMR, and microsatellite instability-high. These genetic anomalies prevent cells from correcting DNA errors, making the tumors highly recognizable to the body's immune system once chemical brakes are removed.[2][5]

For decades, the standard of care for this diagnosis involved a grueling sequence of chemotherapy, targeted radiation, and invasive surgery. That surgical intervention frequently left patients requiring a permanent colostomy bag, fundamentally altering their daily lives and physical autonomy.[1][3]

"This approval represents a paradigm shift in how we approach locally advanced rectal cancer," the FDA noted in its authorization documents. By administering the immunotherapy intravenously, oncologists can now prompt the patient's own immune system to dismantle the tumor entirely.[1]

Shifting the standard of care

The drug, manufactured by British pharmaceutical company GSK, functions as a PD-1 inhibitor. It blocks a specific protein pathway that cancer cells exploit to hide from circulating T-cells, effectively stripping the tumor of its molecular camouflage.[2][7]

Once the PD-1 receptor is blocked, the immune system recognizes the highly mutated dMMR cancer cells as foreign invaders and attacks them. The treatment is administered as an intravenous infusion every three weeks for six months, replacing the traditional surgical route.[3][5]

Clinical data supporting the accelerated approval demonstrated a remarkably high complete response rate among trial participants. In the foundational studies, every patient who completed the six-month regimen saw their tumors vanish entirely, undetectable by physical exam, endoscopy, or MRI.[3][4]

"We are seeing unprecedented outcomes where the cancer is completely eradicated without the life-altering morbidities associated with standard treatments," GSK representatives stated following the regulatory decision. The company emphasized that preserving organ function remains a primary goal for the new therapeutic approach.[2][7]

The genetic requirement

The treatment is not a universal cure for all bowel cancers, as its efficacy depends entirely on the tumor's genetic profile. Only about 5 to 10 percent of all rectal cancers feature the mismatch repair-deficient signature required for dostarlimab to work effectively.[4][5]

Patients must undergo specific biomarker testing before they can be prescribed the immunotherapy. If a biopsy confirms the dMMR or MSI-H status, the patient becomes eligible to bypass the traditional chemotherapy and surgical wards entirely.[1][4]

For the remaining 90 to 95 percent of rectal cancer patients whose tumors lack this specific mutation, standard protocols involving radiation and surgery remain necessary. Researchers are currently investigating whether combining PD-1 inhibitors with other agents might expand this success to broader patient populations.[3][5]

The financial implications of the approval also ripple through the pharmaceutical sector, benefiting development partners like AnaptysBio, which originally discovered the antibody. Market analysts at Morningstar noted that the new indication significantly expands Jemperli's commercial footprint in the oncology space.[6][7]

Accelerated pathways and next steps

Because the FDA utilized its accelerated approval pathway, the authorization is contingent upon ongoing clinical verification. GSK must continue monitoring the initial trial cohorts and conduct larger confirmatory studies to prove that the tumors do not return over the long term.[1][2]

The accelerated mechanism allows the agency to bring drugs for serious conditions to market faster when early clinical data shows a profound advantage over existing therapies. If follow-up data fails to confirm the sustained clinical benefit, the FDA retains the authority to withdraw the indication.[1][4]

Adverse reactions reported during the trials were generally manageable and consistent with other immune-checkpoint inhibitors. The most common side effects included fatigue, nausea, diarrhea, and localized rash, though severe immune-mediated reactions remain a documented risk.[1][5]

Oncologists are now tasked with integrating this non-operative approach into community cancer centers across the United States. The shift requires close coordination between medical oncologists, who administer the infusions, and surgical oncologists, who must monitor patients to ensure the tumors have truly disappeared.[3][4]

Prioritizing organ preservation

The elimination of radiation therapy also spares patients from long-term pelvic toxicity, which frequently causes chronic pain, sexual dysfunction, and secondary malignancies. By avoiding these collateral damages, younger patients diagnosed with rectal cancer can maintain their fertility and normal physiological functions.[1][5]

The FDA's decision aligns with a broader oncology movement termed organ preservation, which prioritizes quality of life alongside overall survival rates. As systemic therapies become more precise, the reliance on anatomical resection continues to decrease across multiple cancer disciplines.[3][4]

For the hundreds of Americans diagnosed annually with this specific genetic variant of rectal cancer, the regulatory green light offers an immediate alternative to the operating room. The focus now shifts to ensuring equitable access to the biomarker testing required to identify eligible candidates.[1][7]

The definitive metric for the immunotherapy will be the five-year survival and recurrence data, which will mature over the coming decade. Until then, the October 2026 approval stands as a major milestone in the push to replace surgical oncology with precision immunology.[2][5]